EU Approval Recommendation Secures Ibrance Domination
Executive Summary
The EMA’s CHMP has recommended Ibrance for HR+/HER2- breast cancer and Pfizer may be able to establish a dominant position in the EU even quicker than it did in the US.
You may also be interested in...
Lilly's Abemaciclib Hit Leaves It Down But Not Out
Continuation of Phase III MONARCH 2 study, with no early termination for efficacy, may mean a delay in filing and a tougher competitive outlook against Pfizer's Ibrance and Novartis' ribociclib.
Novartis Ups Pace On Ibrance Challenger As Ribociclib Trial Stopped Early
Novartis's Phase III MONALEESA-2 trial of its CDK4/6 inhibitor ribociclib has been stopped early on positive interim data. The study was conducted in first-line metastatic, hormone-positive breast cancer patients, a market estimated to be worth $6bn in the US alone.
HR+/HER2- Breast Cancer Market Set To Triple
The HR-positive/HER2-negative breast cancer market is set to more than triple in value by 2022, according to a new forecast by Datamonitor Healthcare. The growth will be driven by a marketed product as well as the approval of several late-phase pipeline candidates. Generic and biosimilar drugs are expected to offset these sales from the beginning of 2023.